PAM
FBRX icon

Panagora Asset Management’s Forte Biosciences FBRX Stock Holding History

Panagora Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2
Closed -$10K – 2371
2017
Q2 		$10K Buy
+2
New +$11.3K ﹤0.01% 2391

Other funds holding FBRX

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Panagora Asset Management's FBRX Position: Q3 2017 in Review

Panagora Asset Management sold out of Forte Biosciences (FBRX) in Q3 2017, closing a stake of 2 shares — an estimated $10K sold.

Panagora Asset Management first reported a position in FBRX in Q2 2017 and held it in 1 quarter. The position peaked at $10K in Q2 2017. 44 funds tracked by Wall St. Rank hold FBRX as of Q3 2017.

  • Panagora Asset Management reported no remaining Forte Biosciences position as of Q3 2017 after selling out during the quarter.
  • Panagora Asset Management sold 2 Forte Biosciences shares in Q3 2017, an estimated $10K.
  • Panagora Asset Management first reported a position in Forte Biosciences in Q2 2017 and held it in 1 quarter.
  • Panagora Asset Management's Forte Biosciences position peaked at $10K in Q2 2017.
  • 44 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2017.

Based on Panagora Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.